8 recruiting, 7 terminated, 3 completed, 3 not yet recruiting. 14 Phase 2, 6 Phase 1, 6 Phase 3.
Follow futibatinib: new trials by email Literature Review of futibatinib trials Research Report on futibatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-12-10 | 2026-06-10 |
| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 1 | Not yet recruiting | Northwestern University | 18 | 2027-09-09 | 2026-10-20 |
| Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Not yet recruiting | UNICANCER | 990 | 2027-01-02 | 2026-08-04 |
| Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer Futibatinib, Zimberelimab, Durvalumab - Biliary Tract Cancer | Phase 3 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 784 | 2026-06-24 | 2026-07-17 |
| Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Biospecimen Collection, Computed Tomography, Durvalumab - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 2 | Recruiting | Yuanquan Yang | 24 | 2024-12-30 | 2026-10-01 |
| Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. futibatinib, futibatinib, fulvestrant - Advanced/Metastatic Cancer | Phase 2 / Phase 3 | Active not recruiting | Taiho Oncology, Inc. | 15 | 2024-10-01 | 2026-07-28 |
| Personalized Medicine for Advanced Biliary Cancer Patients Futibatinib, Ivosidenib, Zanidatamab - Biliary Tract Neoplasms | Phase 3 | Recruiting | UNICANCER | 800 | 2024-07-18 | 2026-05-19 |
| Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Futibatinib, Pembrolizumab, Cisplatin - Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma | Phase 2 | Active not recruiting | Taiho Oncology, Inc. | 53 | 2023-07-13 | 2026-09-01 |
| Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement TAS-120 - Advanced Cholangiocarcinoma, FGFR2 Fusions | Phase 2 | Recruiting | Taiho Oncology, Inc. | 120 | 2023-07-05 | 2026-09-01 |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications BBI-355, Erlotinib, Futibatinib - Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Terminated | Boundless Bio, Inc. | 85 | 2023-03-24 | 2026-08-19 |
| A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Futibatinib, Pembrolizumab - Metastatic Cancer, Endometrium Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2021-09-30 | 2026-03-27 |
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer Futibatinib and Binimetinib - Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Taiho Oncology, Inc. | 38 | 2021-09-20 | 2024-09-19 |
| Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer Futibatinib, Pembrolizumab, Quality-of-Life Assessment - Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma | Phase 2 | Completed | Mayo Clinic | 14 | 2021-08-17 | 2025-11-18 |
| AB122 Platform Study AB122, TAS-116, TAS-120 - Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 917 | 2021-06-01 | 2026-08-05 |
| Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma Futibatinib, Pembrolizumab - Advanced and Metastatic Urothelial Cancer | Phase 2 | Terminated | Taiho Oncology, Inc. | 43 | 2021-01-07 | 2025-12-31 |
| Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements Futibatinib, Cisplatin, Gemcitabine - Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements | Phase 3 | Terminated | Taiho Oncology, Inc. | 10 | 2021-01-06 | 2025-02-07 |
| Futibatinib in Patients With Specific FGFR Aberrations Futibatinib - Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer | Phase 2 | Terminated | Taiho Oncology, Inc. | 115 | 2020-08-05 | 2025-10-08 |
| A Study of TAS-120 in Patients With Metastatic Breast Cancer Futibatinib, Futibatinib plus Fulvestrant - Metastatic Breast Cancer, FGFR 1 High Amplification | Phase 2 | Terminated | Taiho Oncology, Inc. | 64 | 2020-01-28 | 2025-11-13 |
| Molecular Profiling of Advanced Soft-tissue Sarcomas Nilotinib, Ceritinib, Capmatinib - Soft Tissue Sarcoma | Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 603 | 2019-10-19 | 2026-04-29 |
| A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) Atezolizumab, Futibatinib, Amivantamab - Advanced Solid Tumor | Phase 2 | Recruiting | Vall d'Hebron Institute of Oncology | 1000 | 2018-12-10 | 2024-04-25 |
Showing 20 of 24. Sign in to see all of them.
Cholangiocarcinoma (5) · Neoplasm Metastasis (5) · Biliary Tract Neoplasms (4) · Neoplasms (3) · Stomach Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Neoplasms (2) · Acrocephalosyndactylia (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1)
Taiho Oncology, Inc. (10) · Northwestern University (2) · Taiho Pharmaceutical Co., Ltd. (2) · UNICANCER (2) · American Society of Clinical Oncology (1) · Boundless Bio, Inc. (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Vall d'Hebron Institute of Oncology (1) · Yuanquan Yang (1)
United States (17) · France (11) · Spain (10) · United Kingdom (8) · Italy (7) · Japan (6) · South Korea (6) · Germany (5) · Netherlands (5) · Australia (4) · Hong Kong (4) · Portugal (4) · Belgium (3) · Canada (3) · Argentina (2)
Julien Edeline, MD (2) · Antoine Italiano (1) · Birgit Geoerger, MD (1) · Gladys Rodriguez, MD (1) · Ivan Borbath, MD (1) · John Bridgewater, MD (1) · Jordi Rodon, MD (1) · Juan W Valle (1) · Malka David, MD (1) · Nguyen H. Tran, M.D. (1) · Robert Doebele, MD, PhD (1) · Shishir K Maithel, MD (1) · Yuanquan Yang, MD, PhD (1)
PMID 31538815, PMID 32622884, PMID 32713836, PMID 33068284, PMID 33090333, PMID 33844595, PMID 33892407, PMID 34347542, PMID 34543871, PMID 34740331, PMID 35292802, PMID 36315917, PMID 36652354, PMID 36753688, PMID 37027810, PMID 37315265, PMID 37489819, PMID 37561967, PMID 37972659, PMID 38039429, PMID 38096472, PMID 38354330, PMID 38564684, PMID 38748939, PMID 38865672, PMID 38884254, PMID 39013131, PMID 39413339, PMID 40610648, PMID 41100773, PMID 41538762, PMID 41838385, PMID 42018965, PMID 42060861, PMID 42149426, PMID 42456088, PMID 42686334, PMID 42842844
2019 (3), 2017 (2), P30CA060553 (2), 2016 (1), 2023 (1), 2025 (1)